FIND is collating an overview of SARS-CoV-2 tests that are commercially available or in development for the diagnosis of COVID-19. We do not guarantee that this is a comprehensive list, since the information below has been submitted voluntarily by test suppliers and is not independently verified. Please find the latest lists on the websit

Tests zur Detektion einer Infektion mit SARS-CoV-2 (neuartiges Coronavirus) sowie zum Nachweis von Antikoerpern gehoeren zu den sog. In-vitro-Diagnostika (IVD). Das erstmalige Inverkehrbringen von In-vitro-Diagnostika auf dem deutschen Markt ist nach §§ 25 und 30 Medizinproduktegesetz (MPG) anzeigepflichtig. Das DIMDI betreibt dafuer die Datenbank "In-vitro-Diagnostika-Anzeigen (MPIVDA)", in welcher demnach auch Daten von "Corona-Tests" von den anzeigepflichtigen deutschen Herstellern und Bevollmaechtigten bzw. Einfuehrern erfasst werden

The purpose of this document is to provide guidance on the use of pooled sample testing strategy in coronavirus disease (COVID-19) testing laboratories of the African Union Member States for scaling up SARS-CoV-2 nucleic acid testing capacity with the available resources. The current document describes the effect of factors such as the prevalence of COVID-19 in the population to be tested, the homogeneity of pools, and the sensitivity of the molecular test in optimal pool size determination. It also highlights the importance of monitoring the prevalence of COVID-19 in a population to be tested and proper validation of the test, to limit the potential for false-negative results. Validation studies to determine the optimal pool size by testing laboratories are recommended as the optimum approach. A safe, simple ‘two-stage pooling’ option has been indicated in this guidance to be used by laboratories until such validation can be achieved

Interim guidance, 11 September 2020 A new technology for COVID-19 detection has become available that is much simpler and faster to perform than currently-recommended nucleic acid amplification tests (NAAT), like PCR. This method relies on direct detection of SARS-CoV-2 viral proteins in nasal swabs and other respiratory secretions using a lateral flow immunoassay (also called an RDT) that gives results in < 30 minutes. Though these antigen detection RDTs (Ag-RDTs) are substantially less sensitive than NAAT, they offer the possibility of rapid, inexpensive and early detection of the most infectious COVID-19 cases in appropriate settings. Acknowledging the inadequacy of current data on the performance and operational utility of these tests, this document seeks to provide guidance to countries on considerations for integration into COVID-19 outbreak management programs

8 July 2020

A pulse oximeter is a small device that can typically be clipped on a finger (toe or earlobe is also possible) to measure oxygen levels in the blood. This works completely painless and will give you a reading within a few seconds

The speed of developing diagnostics for SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has been quite remarkable. Diagnostics have focused on nucleic acid amplification testing (NAAT) to identify infected individuals in acute-phase disease for timely implementation of mitigation strategies and case management. More and more immunodiagnostics, mostly rapid diagnostic tests, are being made available as an alternative to NAATs. This type of test can be used out-of-laboratory conditions at large scale

New England Journal of Medicne NJM 2020 382, 22 You can download the video here https://medbox.org/document/how-to-obtain-a-nasopharyngeal-swab-specimen-video#GO